Bio-Techne (TECH) AI Stock Analysis

• Market Cap: $8.50B
• Dividend Yield: 0.6%
• Average Volume (3M): 2.34M
• Price to Earnings (P/E): 116.3
• Beta (1Y): 0.92
• Revenue Growth: 5.23%
• EPS Growth: -56.70%
• Country: US
• Employees: 3,100
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): 0.53
• Shares Outstanding: 155,549,590
• 10 Day Avg. Volume: 1,967,127
• 30 Day Avg. Volume: 2,336,293
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.97
• Enterprise Value/Revenue: 6.77
• Enterprise Value/Gross Profit: 10.44
• Enterprise Value/Ebitda: 36.99
• 1Y Price Target: $66.00
• Price Target Upside: 23.73% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 13

• Rating: 64 Neutral
• Price Target: $57.00 ▲(6.86% Upside)

Bio-Techne's overall stock score is driven by a stable financial position and strategic initiatives to improve profitability, as highlighted in the earnings call. However, high valuation metrics and technical indicators suggest caution. The company's ability to navigate market uncertainties and improve operational efficiency will be crucial for future performance.

Positive Factors

Financial Performance

The financial results showed a slight beat on revenue and profitability metrics were better than expected.

Organic Growth

Techne is considered one of the best-positioned companies to see growth despite uncertainties.

Strategic Divestitures

The recent divestiture of ExoDx allows Bio-Techne to free up capital, improve margins, and invest further in its strategic growth areas.

Negative Factors

Growth Outlook

Management expects organic growth to be in the low single digits due to macro uncertainties.

Macro Headwinds

Shares traded down due to macro headwinds such as NIH, pharma tariffs, and biotech funding challenges.

Policy Uncertainties

Management's preliminary guidance came as a surprise with lower than expected growth projections due to ongoing policy uncertainties.

Bio-Techne Business Overview & Revenue Model

Company Description

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

How the Company Makes Money

Bio-Techne makes money primarily through the sale of its diverse range of biotechnology products and solutions. Key revenue streams include sales of proteins and antibodies, which are essential components for research and development in life sciences. The company also generates significant income from its immunoassay and diagnostic products, which are widely used in clinical settings to detect and quantify biological markers. Additionally, Bio-Techne benefits from partnerships and collaborations with academic institutions, research organizations, and pharmaceutical companies, enhancing its market reach and contributing to its earnings.

Bio-Techne Financial Statement Overview

Summary

Bio-Techne shows a stable financial position with strong cash flow generation and prudent leverage. However, declining profitability margins and inconsistent revenue growth pose challenges. The company needs to address operational inefficiencies to improve overall financial performance.

Income Statement

Bio-Techne's revenue growth has been inconsistent, with a significant drop in growth rate in the latest year. Gross profit margin remains strong, but net profit margin has decreased, indicating rising costs or inefficiencies. EBIT and EBITDA margins have also declined, suggesting pressure on operational profitability.

Balance Sheet

The company maintains a healthy debt-to-equity ratio, indicating prudent leverage management. However, return on equity has decreased, reflecting lower profitability. The equity ratio is stable, showing a solid capital structure.

Cash Flow

Operating cash flow remains robust, with a strong coverage ratio. Free cash flow growth is positive, though it has slowed down. The free cash flow to net income ratio is high, indicating efficient cash generation relative to earnings.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.22B	1.22B	1.16B	1.14B	1.11B	931.03M
Gross Profit	790.27M	790.27M	769.73M	769.82M	756.50M	632.85M
EBITDA	223.07M	216.88M	310.37M	460.56M	420.12M	258.47M
Net Income	73.40M	73.40M	168.10M	285.26M	272.05M	140.41M
Balance Sheet
Total Assets	2.56B	2.56B	2.70B	2.64B	2.29B	2.26B
Cash, Cash Equivalents and Short-Term Investments	162.19M	162.19M	152.86M	204.31M	247.03M	231.55M
Total Debt	444.06M	444.06M	419.54M	454.96M	325.97M	420.55M
Total Liabilities	639.06M	639.06M	635.02M	672.18M	593.79M	691.72M
Stockholders Equity	1.92B	1.92B	2.07B	1.97B	1.70B	1.57B
Cash Flow
Free Cash Flow	256.55M	256.55M	236.10M	216.15M	280.36M	307.86M
Operating Cash Flow	287.56M	287.56M	298.98M	254.39M	325.27M	352.16M
Investing Cash Flow	-35.18M	-35.18M	-203.03M	-265.65M	-96.85M	-243.52M
Financing Cash Flow	-253.91M	-253.91M	-122.40M	22.62M	-242.85M	-62.55M

Bio-Techne Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 53.34
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TECH, the sentiment is Negative. The current price of 53.34 is below the 20-day moving average (MA) of 53.69, below the 50-day MA of 53.67, and below the 200-day MA of 59.99, indicating a bearish trend. The MACD of 0.29 indicates Positive momentum. The RSI at 46.64 is Neutral, neither overbought nor oversold. The STOCH value of 25.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TECH.

Bio-Techne Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HALO	79 Outperform	$8.56B	16.75	179.14%	―	34.97%	71.10%
CORT	73 Outperform	$7.35B	63.52	21.42%	―	25.71%	4.48%
TECH	64 Neutral	$8.50B	116.31	3.68%	0.60%	5.23%	-56.70%
JAZZ	64 Neutral	$7.87B	15.58	-10.84%	―	4.52%	-205.13%
ROIV	61 Neutral	$8.46B	1.93	-15.84%	―	-85.32%	-111.82%
RYTM	55 Neutral	$6.92B	―	-1334.54%	―	53.55%	30.87%
Sector *	51 Neutral	$7.90B	-0.33	-41.69%	2.23%	23.45%	-1.99%

Bio-Techne Corporate Events

Bio-Techne Divests Exosome Diagnostics to Boost Growth

Bio-Techne reported its fourth quarter fiscal 2025 results, highlighting a 3% organic revenue increase to $317.0 million and a full-year organic revenue growth of 5% to $1.2 billion. Despite a decrease in GAAP EPS to ($0.11) from $0.25 a year ago, adjusted EPS rose to $0.53 from $0.49. The company announced the divestiture of its Exosome Diagnostics business to focus on high-growth areas, which is expected to enhance profitability. The Protein Sciences segment showed strong growth, while the Diagnostics and Spatial Biology segment faced challenges due to unfavorable product mix.